Final analysis of the phase 4 EXELS trial in high-risk patients with essential thrombocythemia

At the 20th Congress of the European Hematology Association (EHA), Claire Harrison, MD, DM, FRCP, FRCPath, of Guy’s and St Thomas’ NHS Foundation Trust, London, UK, discusses the final results of the Evaluation of Xagrid® Efficacy and Long-term Safety (EXELS) trial. EXELS is an observational phase 4 trial that compared safety, pregnancy outcomes, and efficacy, measured by incidence of thrombohaemorrhagic events and platelet reduction, of anagrelide compared with other cytoreductive therapies in high-risk patients with essential thrombocythemia.

Share this video  
12th June 2015